# International Paper Co.

**IP**

NYSE; manufacturing; SIC 2621, Paper Mills; CIK 0000051434


# None

### No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $38.0B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | thin data<br>not computable: dilution, distress |
| **Inputs computable** | 6 of 14 |
| **Graded from** | filings received through Feb 27, 2026<br>253 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026 |
| **Last close** | $34.53<br>2026-11-06; market equity $0; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 27, 2026*

International Paper Company (the "Company," "International Paper" or "IP", which may also be referred to as "we" or "us") is a global leader in sustainable packaging solutions. We produce renewable fiber-based packaging products with manufacturing operations in North America, Latin America, Europe and North Africa. We are a New York corporation, incorporated in 1941 as the successor to the New York corporation of the same name organized in 1898. In recent years, the Company has undergone significant transformation designed to simplify our operations, strengthen performance and position the business for long-term value creation.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 23.7** | | | | | | |
| Gross profitability | 18.4% | 21.9% | | 57.3 | 275 | 2025-12-31 |
| Return on invested capital | not computable | 9.7% | | | | |

*required facts have no common fiscal period end*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (17.2%) | (3.6%) | 10.2 | 306 | 2025-12-31 |
| Gross margin stability, five years | 0.6 pts | 2.1 pts | 3.5 | 229 | 2025-12-31 |
| **Solvency, sleeve percentile 81.1** | | | | | |
| Twelve-month failure probability | not computable | 0.04% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |
| Altman Z double-prime | not computable | 3.66 | | | |
| *one or more required annual facts are missing* | | | | | |
| Net debt to EBITDA | not computable | 1.78x | | | |
| *required facts have no common fiscal period end* | | | | | |
| Interest coverage | not computable | 5.09x | | | |
| *latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 1.28x | 2.25x | 81.1 | 323 | 2025-12-31 |
| **Growth and financing, sleeve percentile 28.1** | | | | | |
| Revenue growth, three-year compound | 3.8% | 2.2% | 41.0 | 269 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 13.5% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 26.1% | | | |
| *latest aligned inputs end 2015-12-31; latest annual assets end 2025-12-31* | | | | | |
| Asset growth, three years | 16.6% | 4.3% | 15.2 | 277 | 2025-12-31 |
| Net share issuance, one year | not computable | 0.01% | | | |
| *firm-wide XBRL shares cannot be assigned to one ticker class* | | | | | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 6 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-06 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (9.9%) | 9.8% | 29 |
| Distance from 52-week high | (29.8%) | (27.4%) | 44 |
| EBIT to enterprise value | not computable | 4.2% | |
| Free cash flow yield | not computable | 3.5% | |
| Book value to price | not computable | 0.37 | |
| Sales to price | not computable | 0.55 | |
| Composite equity issuance, five years | not computable | (9.6%) | |
| Relative strength against the sector, log excess return | (0.19) | 0.01 | 29 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | pass |
| Asset turnover improved | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $815.0M |
| Operating cash flow, four quarters | $2.4B |
| Months of runway | not finite |
| Days since last periodic filing | 3 (10-Q received Nov 4, 2026) |
| Median daily dollar volume, 63 sessions | $173.0M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $23.6B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $16.6B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 3 | assets | us-gaap:Assets | $38.0B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 4 | net income | us-gaap:NetIncomeLoss | -$3.5B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 5 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $1.7B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 6 | assets | us-gaap:Assets | $22.8B | 2024-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 7 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $15.8B | 2024-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 8 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $11.4B | 2024-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 9 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $16.0B | 2023-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 10 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $11.5B | 2023-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 11 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $21.2B | 2022-12-31 | 2025-02-21 | 10-K | 25-000013 |
| 12 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $15.1B | 2022-12-31 | 2025-02-21 | 10-K | 25-000013 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $19.4B | 2021-12-31 | 2024-02-16 | 10-K | 24-000024 |
| 14 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $13.8B | 2021-12-31 | 2024-02-16 | 10-K | 24-000024 |
| 15 | operating income | us-gaap:OperatingIncomeLoss | $2.4B | 2015-12-31 | 2016-02-25 | 10-K | 16-000042 |
| 16 | interest expense | us-gaap:InterestExpense | $644.0M | 2015-12-31 | 2018-02-22 | 10-K | 18-000008 |
| 17 | current assets | us-gaap:AssetsCurrent | $10.1B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 18 | current liabilities | us-gaap:LiabilitiesCurrent | $7.9B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $1.9B | 2025-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $1.7B | 2024-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $921.0M | 2024-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $1.8B | 2023-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $1.1B | 2023-12-31 | 2026-02-27 | 10-K | 26-000055 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $2.2B | 2022-12-31 | 2025-02-21 | 10-K | 25-000013 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $931.0M | 2022-12-31 | 2025-02-21 | 10-K | 25-000013 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquireProductiveAssets | $1.3B | 2015-12-31 | 2018-02-22 | 10-K | 18-000008 |
| 27 | depreciation amortization | us-gaap:Depreciation | $1.1B | 2015-12-31 | 2018-02-22 | 10-K | 18-000008 |
| 28 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $1.1B | 2015-12-31 | 2018-02-22 | 10-K | 18-000008 |
| 29 | income tax | us-gaap:IncomeTaxExpenseBenefit | $417.0M | 2015-12-31 | 2018-02-22 | 10-K | 18-000008 |
| 30 | current assets | us-gaap:AssetsCurrent | $6.5B | 2015-12-31 | 2017-02-22 | 10-K | 17-000007 |
| 31 | current liabilities | us-gaap:LiabilitiesCurrent | $3.9B | 2015-12-31 | 2017-02-22 | 10-K | 17-000007 |
| 32 | current assets | us-gaap:AssetsCurrent | $8.0B | 2014-12-31 | 2016-02-25 | 10-K | 16-000042 |
| 33 | current liabilities | us-gaap:LiabilitiesCurrent | $4.9B | 2014-12-31 | 2016-02-25 | 10-K | 16-000042 |
| 34 | assets | us-gaap:Assets | $23.3B | 2023-12-31 | 2025-02-21 | 10-K | 25-000013 |
| 35 | assets | us-gaap:Assets | $23.9B | 2022-12-31 | 2024-02-16 | 10-K | 24-000024 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.